Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
about
Therapeutic insights from genomic studies of head and neck squamous cell carcinomasActivation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cellsActivation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.Nanoimmunoassay to Detect Responses in Head and Neck Cancer: Feasibility in a Mouse Model.Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of head and neck cancers.Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery.Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyDetection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer PatientsTargeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.Is mammary not otherwise specified-type sarcoma with CD10 expression a distinct entity? A rare case report with immunohistochemical and ultrastructural studyTherapeutic outcome after resection of pulmonary metastasis from head and neck carcinomas.Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck.Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells.Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.The role of recombinant epidermal growth factor and serotonin in the stimulation of tumor growth in a SCCHN xenograft modelLapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibitionAntitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinomaPhase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).Recurrent head and neck cancer: current treatment and future prospects.Head and neck cancer: an evolving treatment paradigm.EGFR family: structure physiology signalling and therapeutic targets.Molecular profiling of head and neck squamous cell carcinoma.Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma.Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications.Differentiated thyroid cancers: a comprehensive review of novel targeted therapies.Autophagic action of new targeting agents in head and neck oncology.Imaging EGFR and HER2 by PET and SPECT: a review.Relationship between head and neck cancer therapy and some genetic endpointsPrevalence of EGFR Tyrosine Kinase Domain Mutations in Head and Neck Squamous Cell Carcinoma: Cohort Study and Systematic Review.A simple multicolor flow cytometry protocol for detection and molecular characterization of circulating tumor cells in epithelial cancers.Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB.Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.
P2860
Q27006854-128BED4B-2E13-4CE1-B362-DB5417AF8B75Q30414074-8621689E-537A-43FE-B341-D14D867061B1Q30424348-9504237B-FB75-4294-B5D7-8662599A06E1Q30457748-B2EE3033-4517-4E48-A33A-0CF16CFDB24FQ30482688-42B50459-3DA9-43C6-B9AF-0F8D006C863BQ30486828-B1CEE838-517F-47A4-9F20-852325DCEC47Q33406802-AB218E27-5454-4D84-B7A2-D4B93C24A27BQ33525226-B31FB119-D2A3-4DD0-81E9-AC34E7187A23Q33570512-031792D9-04B4-4B59-B660-D7C64259397BQ33612305-66C252F9-6B3D-4888-A25E-85808CD3E65CQ33809528-64257A75-7260-48BE-BF1D-79309F1AA0D7Q34217687-CC80DDD7-3F21-4EDA-84E0-F6420583B8E0Q34518357-5B43991B-E3B2-459C-82CF-334E669986FAQ34565569-E7F81366-7EFB-473C-BBC2-A5198BCED3D6Q34983366-CB18CA90-70E4-45E2-AA60-798ED47CF860Q35091386-5A31B9F9-1E84-4A83-A4C2-1320161A74AFQ36072292-A38691DC-E00A-43C0-87D1-9BC4F3A00C6BQ36088627-17C9CCBF-D5F7-425A-BD4E-3C4200D4883CQ36613969-B1D17751-69C6-4055-B3D5-D75EC8D62662Q36642153-C0230DE4-3A9E-4F75-9B31-5A8944FB583DQ36717363-D117AF7F-64A1-4C3F-BAF0-56341E60499AQ36865029-E4D86225-E105-4B37-968D-2853F5F03212Q36868012-36980E66-1A85-4E3E-BA32-D170489B79F2Q36909227-EFD37114-0441-46AC-92EE-4C823F020709Q36995781-A3569CD4-7407-4681-AFC0-0D14F325F386Q37118936-3F4B32BF-8E33-4FC1-9B17-4DAD65693395Q37271937-62CA1D02-4D03-4A60-A7D5-4646C07C0669Q37272623-15EF8F2A-FAC3-438E-9468-BDCB15E6C8AAQ37337359-0EB6A96F-639D-4393-9369-09989FD58164Q37359711-6A619D12-4190-4733-A0DD-7DEAAD2DF1A9Q37469890-D8D01B52-84E6-4C18-8626-54EE8B59C135Q37788246-B28A98F6-9AC9-46B3-B27F-6244E668B8C5Q37988566-47AB487E-1DFA-4B0C-889B-98D014387B03Q38028794-B966BC2F-40FA-4F82-89CE-212DB11EE96EQ38137829-21E9922C-6E0A-4011-AD26-44BE1035B338Q38211868-61E74761-DA7E-4A47-9516-AA2CC8117F5EQ39073840-D53DCB6A-1309-42B2-AA29-9931BCC3061FQ39375702-E9B7516B-367F-4AFB-BE5C-4B0E7BE2DF95Q39846889-51C34259-9707-491A-8B64-C854155C630CQ39894634-D35A4C80-04BB-40FB-B6E1-2D965612A927
P2860
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Role of epidermal growth facto ...... arcinoma of the head and neck.
@ast
Role of epidermal growth facto ...... arcinoma of the head and neck.
@en
type
label
Role of epidermal growth facto ...... arcinoma of the head and neck.
@ast
Role of epidermal growth facto ...... arcinoma of the head and neck.
@en
prefLabel
Role of epidermal growth facto ...... arcinoma of the head and neck.
@ast
Role of epidermal growth facto ...... arcinoma of the head and neck.
@en
P356
P1476
Role of epidermal growth facto ...... arcinoma of the head and neck.
@en
P2093
Ezra E W Cohen
P304
P356
10.1200/JCO.2005.05.4577
P407
P577
2006-06-01T00:00:00Z